



# BERYL DRUGS LIMITED

**Regd. Off.:** Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.) INDIA.  
**Tel. :** (0731) 2517677 **E-mail :** beryldrugs25@yahoo.com **CIN : L02423MP1993PLC007840**

**Date: 12<sup>th</sup> February, 2020**

To,  
**The DCS-Listing**  
**The Bombay Stock Exchange Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001


**Scrip Code: 524606**

**Subject: Outcome of 27<sup>th</sup> Board Meeting**

Outcome of the 27<sup>th</sup> meeting of the Board of the Directors of the company held on Wednesday, the 12<sup>th</sup> day of February, 2020 at 03:00 P.M. at the Registered Office 133, Kanchan Bagh, Indore- 452001 (M.P.) of the company wherein the Unaudited Financial Result of the Company for the quarter ended 31<sup>st</sup> December, 2019 were Considered and approved.

**For Beryl Drugs Limited**

*Sanjay Sethi*



**Sanjay Sethi**  
**Managing Director**  
**DIN: 00090277**



**BERYL DRUGS LIMITED**  
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.  
Tel./ Fax 0731-2517677  
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited Financial Result by Companies Other than Banks

Part I		(Rs in 000)					
		Quarter ended		Quarter ended		Year ended	
Particulars		3 months ended (31-12-2019)	Preceding 3 months ended (30-09-2019)	Corresponding 3 months ended in the previous year (31-12-2018)	Year to date figures for current period ended (31-12-2019)	Year to date figures for previous period ended (31-12-2018)	Previous year ended (31-03-2019)
(Refer Notes Below)		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue From Operations						
	Net sales or Revenue from Operations	22518.000	32723.000	30636.000	97544.000	107109.000	129598.000
	Other operating revenues	1126.000	686.000	-526.000	1839.000	833.000	2438.000
	<b>Total Revenue from operations (net)</b>	<b>23644.000</b>	<b>33409.000</b>	<b>30110.000</b>	<b>99383.000</b>	<b>107942.000</b>	<b>132036.000</b>
2	Expenses						
(a)	Cost of materials consumed	12922.000	16685.000	14127.000	49957.000	55529.000	68492.000
(b)	Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-3654.000	-1474.000	-608.000	-3778.000	2184.000	1295.000
(d)	Employee benefit expense	2859.000	2216.000	2462.000	7053.000	6562.000	8455.000
(e)	Finance costs	604.000	235.000	749.000	1825.000	1739.000	1461.000
(f)	Depreciation and amortisation expense	2000.000	1045.000	705.000	4090.000	2121.000	3241.000
(g)	Other Expenses	6938.000	12393.000	10653.000	37491.000	32712.000	41129.000
	<b>Total expenses</b>	<b>21669.000</b>	<b>31100.000</b>	<b>28088.000</b>	<b>91638.000</b>	<b>100847.000</b>	<b>124073.000</b>
3	Profit (loss) from operations before exceptional and extraordinary items and tax	1975.000	2309.000	2022.000	7745.000	7095.000	7963.000
4	Exceptional items	0.000	0.000	0.000	0.000	0.000	0.000
5	Profit (loss) before extraordinary items and tax	1975.000	2309.000	2022.000	7745.000	7095.000	7963.000
6	Extraordinary items	0.000	0.000	0.000	0.000	0.000	0.000
7	Profit (loss) before tax	1975.000	2309.000	2022.000	7745.000	7095.000	7963.000
8	Tax Expense						
	Current tax	0.000	700.000	509.000	1300.000	1803.000	2562.000
	Deferred tax	1051.000	-126.000	105.000	750.000	452.000	-506.000
	Income tax earlier years	0.000	0.000	-32.000	0.000	-32.000	0.000
	<b>Total Tax Expenses</b>	<b>1051.000</b>	<b>574.000</b>	<b>582.000</b>	<b>2050.000</b>	<b>2223.000</b>	<b>2056.000</b>
9	Net Profit (loss) for the period from continuing operations	924.000	1735.000	1440.000	5695.000	4872.000	5907.000
10	Net Profit (loss) from discontinuing operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
11	Tax Expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000	0.000
12	Net Profit (loss) from discontinuing operations after tax	0.000	0.000	0.000	0.000	0.000	0.000
13	Net Profit (loss) for the Period	924.000	1735.000	1440.000	5695.000	4872.000	5907.000
14	Other comprehensive income	-44.000	-7.000	-834.000	-133.000	3017.000	2703.000
15	<b>Total Comprehensive Income</b>	<b>880.000</b>	<b>1728.000</b>	<b>606.000</b>	<b>5562.000</b>	<b>7889.000</b>	<b>8610.000</b>
16	Details of equity share capital						
	Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000
	Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
17	Earnings per share						
i	Basic earnings per share before extraordinary items	0.18	0.34	0.28	1.12	0.96	1.16
ii	Diluted earnings per share before extraordinary items	0.18	0.34	0.28	1.12	0.96	1.16

Notes :

- The Quarterly results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 12th Feb 2020. The Statutory Auditors have carried out a limited review of the results for the quarter ended Dec 31, 2019.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) Prescribed under section 133 of the Companies Act, 2013, & other recognized accounting practices & policies to the extent applicable.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- Previous period exp. have been regrouped / rearranged, wherever necessary.
- Sales is Net of GST.
- The Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

Place : Indore  
Date : 12.02.2020

For and behalf of the Board  
Sanjay Sethi  
Managing Director

# PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: [caprateekjain@gmail.com](mailto:caprateekjain@gmail.com)



## LIMITED REVIEW REPORT

To,  
The Board of Directors  
**Beryl Drugs Limited**  
133, Kanchan Bagh,  
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** ("the Company") for the quarter ended **31<sup>st</sup> December, 2019** attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR PRATEEK JAIN AND CO.**

**CHARTERED ACCOUNTANTS**

**FRN-009494C**

**UDIN:20079214AAAAAN8586**



*Prateek Jain*

**PRATEEK JAIN  
PROPRIETOR  
M. No. 079214**

**Date: 12<sup>th</sup> February, 2020**

**Place: Indore**